Status:

TERMINATED

Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

Lead Sponsor:

Indiana University

Collaborating Sponsors:

Indiana University School of Medicine

Conditions:

Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung. While three ...

Detailed Description

1. Primary Objectives During Phase I study - Determine the safety and maximum tolerated radiation dose for five fraction SABR for squamous cell cancer of the lung. During Phase II study - Determin...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age ≥ 18 at time of consent.
  • Ability to provide written informed consent and HIPAA authorization.
  • Pathological diagnosis of squamous cell carcinoma of the lung.
  • Staging PET/CT (invasive mediastinal staging strongly encouraged but not required).
  • Tumors \< 7cm
  • Any location eligible for SBRT (including, but not limited to, peripheral, chest wall abutting and central tumors)
  • N0 M0 disease
  • Plan to undergo four or five fraction SABR
  • Baseline PFTs available within 6 months of treatment start or will be obtained prior to treatment start (no finding will exclude patient from enrollment in trial)
  • Exclusion Criteria
  • Previous radiation therapy to the lung per investigator discretion.
  • Inability to comply with treatment per investigator discretion.
  • Inability to follow standard of care follow up recommendations per investigator discretion.
  • KPS\<40

Exclusion

    Key Trial Info

    Start Date :

    October 20 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 9 2020

    Estimated Enrollment :

    13 Patients enrolled

    Trial Details

    Trial ID

    NCT03321747

    Start Date

    October 20 2017

    End Date

    July 9 2020

    Last Update

    July 26 2022

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Indiana University Health Hospital

    Indianapolis, Indiana, United States, 46202

    2

    Indiana University Health Methodist Hospital

    Indianapolis, Indiana, United States, 46202

    3

    Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, United States, 46202